Dedicated to ensuring the success of the life science industry in the state of Connecticut
The BioCT Leadership and Board of Directors brings industry expertise, advice, and support to the Connecticut life science community. This team looks forward to serving as mentors and advisors to our members.
BioCT Leadership
Jodie Gillon
President & CEO,
BioCT
Jodie Gillon brings over 25 years of experience in large pharma & biotech having started her career in advocacy and hospitals, in the US and abroad. With vast expertise leading key functions, she is sought after as an advisor to Incubators and Innovation Centers, and as a consultant for biotech, AI, RWE, digital health, and non profit organizations.
Jodie most recently served as the SVP of Corporate Affairs and Patient Advocacy building out the Patient, Medical, and Corporate Affairs functions at Peptilogics, a Phase I and Machine Learning start up. She previously served as the Chief Patient Officer and Head of Clinical Affairs Affairs at Abeona Therapeutics, a cell and gene therapy company. Prior to joining Abeona, Jodie cumulatively spent over a decade with Pfizer as the Global Medical Lead, Patient Engagement, for the Rare Diseases Business Unit and the Director, Medical Communications, within the Chief Medical Office. Prior to Pfizer, Jodie was the Head of Patient Advocacy and Professional Affairs with Achillion Pharmaceuticals where she led Policy, Alliances, Patient Engagement, Contributions/Grants, Compassionate Use, Medical Information, Medica Communications, Field Medical, and External Affairs. Previously she served as the Head of the Chief Medical Office (CMO) of AstraZeneca, where she managed Patient Engagement, Compassionate Use, Trial and Payment Transparency, Meetings and Events, an HCP Engagement Center, Companywide policy, External contributions, Alliances, and Crisis management. Jodie held additional roles as the Global Communications lead at Novartis, Director of Medical Education for Oridion Medical and as a Health Economist with the Israeli Center for Disease Control and Ministry of Health.
She holds a Master’s of Public Health with a dual degree in Health Economics and Epidemiology from Hebrew University in Jerusalem and a BSFS from Georgetown’s School of Foreign Service. She currently serves on several industry wide Boards and Committees, has published and spoken externally across a wide variety of topics and mentors students and female professionals across our industry. While a native New Yorker, Jodie fell in love with New Haven while at Achillion and is proud to call Connecticut her permanent home for three years now. She is eager to contribute to the budding ecosystem here and welcomes you to connect with her.
Stanley Choy, M.B.A.
Co-Chair & Treasurer,
Bioscience Entrepreneur
Mr. Choy is an accomplished executive and entrepreneur with over 30 years of cross-functional experience in the healthcare, biotechnology and professional services industries. He is the co-founder of SHY Therapeutics and provides financial and advisory services to early stage, start-up companies. Currently, Mr. Choy is the Chief Financial Officer for Alphina Therapeutics, Inc, and is the Chief Operating Officer for HLK Phamacin, both biotechnology start-up companies.
Earlier in his career, Mr. Choy served as the Vice President, Finance and Administration at Kolltan Pharmaceutics; a Yale affiliated spin-out. Prior to joining Kolltan, Mr. Choy was the Chief Financial Officer for a leading New York/Boston based law firm and was the Controller for Shearman & Sterling. During his tenure at Pfizer, Mr. Choy held several finance positions including finance director of business planning for the Consumer Health Care Division (acquired by Johnson & Johnson), finance director of the Asia & Latin America Region for the Animal Health Care Division (a.k.a., Zoetis, Inc.), and finance director of the US and Asia Region for the Corporate Finance and Treasurer’s Division. He was also instrumental in the integration of the Warner Lambert and Pharmacia acquisitions. Mr. Choy started his career with Arthur Andersen and Company.
Mr. Choy serves as the director and co-chairman of BioCT, the bioscience industry association for the state of Connecticut. He is on the Advisory Board to the BioCT Innovation Commons, a biotechnology start-up incubator in northeastern Connecticut.
Paul Hughes, J.D.
Secretary,
Partner, Wiggin and Dana, LLP
Paul Hughes is a wiggin(x) co-founder and partner, co-chair of Wiggin’s ECVC practice group, partner in corporate and health care departments, and former managing partner of the firm. Paul brings the perspective of a strategic counselor as well as a successful operator. Leveraging three decades of experience, he has been in the middle of some of the world’s most important business transformations, including the digital revolution, the birth and initial boom of the biotech industry, and the advent of managed health care. Paul loves interacting with entrepreneurs tackling big problems and transforming the way we live, and he brings practical solutions to the problems they face.
As such, Paul has broad experience representing venture capital investors as well as advising and operating both emerging and mature companies in industries including software, life sciences, energy, communications, health care, specialty manufacturing, and fintech.
Advising businesses throughout their life cycles on the full range of corporate issues as outside general counsel, Paul focuses on entity formation, obtaining and structuring financing, mergers and acquisitions, intellectual property transactions, divestitures, spin-offs, joint ventures, and strategic alliances.
Outside of the law, Paul enjoys watching the Boston Bruins, racing sailboats, playing golf, and spending time with his wife, their three adult children, and their two black lab rescue dogs.
David I. Scheer, M.S.
Co-Chair,
President, Scheer and Company
Since 1981, David Scheer has led Scheer & Company, Inc., renowned for its successful track record in building and advising life sciences companies. His expertise stems from a decade-long affiliation with Oak Investment Partners, specifically their Health Care Investing Team. Currently, he chairs the boards of four private firms, including BiologicsMD and Adela, Inc., and has co-founded and served on the boards of various others, such as Achillion Pharmaceuticals, Viropharma, and OraPharma.
In his advisory role, Scheer excels in portfolio strategy and diverse corporate transactions, including startups, partnerships, M&A, and IPOs. He has been a senior advisor to CEOs at institutions like the Hospital for Sick Children and the University Health Network in Toronto, focusing on research commercialization. He actively supports startups based on intellectual property from esteemed institutions, including Yale, Children’s Hospital Boston, and the University of Pennsylvania. Additionally, he holds leadership roles in organizations such as BioCT and the Soderstrom Scholars Fund and serves on advisory committees for global health initiatives and medical schools. With a background in biochemistry from Harvard College and an M.S. in Cell, Molecular, and Developmental Biology from Yale University, Mr. Scheer combines academic knowledge with practical experience to make impactful contributions to the life sciences industry and beyond.
BioCT Board of Directors
Abhijit (Jit) Banerjee, Ph.D., M.B.A.
Associate Vice President, Innovation & Entrepreneurship,
University of Connecticut
Reporting to the Vice President for Research, Innovation and Entrepreneurship, Dr. Banerjee supports UConn’s continued growth as an economic driver for the state of Connecticut by helping to set an agenda that defines the University’s program in technology commercialization. He is responsible for all aspects of the University’s technology commercialization activities, including patenting, licensing, venture development, and UConn’s business incubator, the Technology Incubation Program (TIP).
Robert Bettigole, MPPM
Managing Partner,
Elm Street Ventures
Rob is a Managing Partner of Elm Street Ventures, a New Haven-based seed and early stage venture capital fund that he founded in 2006, working closely with the Yale Investment Office and Yale Ventures. Since inception, ESV has invested in 32 companies, of which 19 have licensed Yale technology.
Rob serves on the boards of P2 Science (where he is Chairman) and Allyx Therapeutics, both Yale spinouts. Previously, He was a board member of AxioMx, Occam Sciences, SeeClickFix, ShareGrove, and Retail Optimization Inc., and served as an observer on the boards of Affomix, Arvinas, BioRelix, Device42, Halda Therapeutics, and Metagenomix. He has a BS in Engineering and Applied Science from Yale University and an MPPM from the Yale School of Management, where he is a Lecturer in entrepreneurship. Rob is a Licensed Professional Engineer and holds several U.S. and foreign patents. He served on the Operating Board of the Yale Entrepreneurial Institute from 2007 to 2017, on the Investment Committee of the College Street Innovation Fund (formerly the YEI Innovation Fund), which ESV managed, and on the Board of New Haven Innovation Collaborative. He is an Entrepreneur-in-Residence at Yale Ventures.
Jean-Michel Boers, M.B.A.
US Country Managing Director, President and CEO
Boehringer Ingelheim
Jean-Michel Boers was appointed U.S. Country Managing Director, President and CEO effective August 1, 2020. Prior to his current role he was responsible for the U.S. Human Pharma business since January 2017 as President of Boehringer Ingelheim Pharmaceuticals, Inc. He steered the successful growth and development of the company’s primary and specialty care portfolio, while positioning the organization for future indication and product launches in areas of unmet medical need.
After starting his career with a German management consulting firm, Mr. Boers joined Boehringer Ingelheim in 1998 and advanced through diverse international leadership roles, including Corporate Vice President of Marketing and Sales Effectiveness at the global headquarters in Ingelheim Germany, Country Managing Director in France and Head of Human Pharma for a newly formed European regional operating unit. In July 2016, he moved to the US initially heading the Specialty Care franchise before taking leadership of the Human Pharma business in 2017.
Mr. Boers earned an M.A. in Social and Economic History from the University of Nijmegen (Netherlands) and an M.B.A. from the University of Texas.
Kat Kayser-Bricker, Ph.D.
Chief Scientific Officer,
Halda Therapeutics
Dr. Kayser-Bricker is the Chief Scientific Officer at Halda Therapeutics and serves on the board of Modifi Bio as an independent director. Kat led Halda in the invention and establishment of a novel drug modality for oncology called RIPTAC™ Therapeutics. She is responsible for scientific and corporate strategy, setting budgets, and presenting operating plans to the board of directors and founder. Kat leads the day-to-day execution of strategy, operations, IP strategy/management, and external communications.
During Kat’s years as a key scientific leader at FORMA Therapeutics, she witnessed the journey of the Series A private company to an IPO and subsequent acquisition in 2022 by Novo Nordisk for $1.1B. She held several roles of increasing responsibility with her last role being Head of Early Discovery Chemistry where she was a leader responsible for expanding the company’s portfolio. Kat successfully led several technology initiatives and programs during her time at FORMA that resulted in major collaboration milestones of >$80M.
Kat is the co-chair of the Executive Women in Bio Connecticut chapter and a member of the Humanity Talent Network (HTN) Advisory Board and Chair of the Chief Scientific Officer Collective.
Kat received her Ph.D. in organic chemistry from Yale University and her B.S. in Biochemistry from the University of Maryland, College Park.
Seng H. Cheng, Ph.D.
Senior Vice President of Research and Product Development,
Alexion, AstraZeneca Rare Disease
Dr. Cheng is responsible for drug discovery, process development and clinical supply as well as clinical biomarkers and bioanalytical discovery, diagnostics, and bioinformatics, supporting the enterprise’s pipeline from target discovery through post-marketing. He also leads and manages the initiative to advance the development of genomic medicines toward clinical development.
Seng was previously Senior Vice President & Chief Scientific Officer of the Rare Disease Research Unit at Pfizer. Prior to joining Pfizer, he was Global Head of Research of Rare Diseases at Sanofi and before that, he was Group Vice President of Genetic Diseases Science at Genzyme. He has contributed to the development of several medicines for rare diseases, co-authored 283 research articles and reviews and is a named inventor on 64 issued US patents in biotechnology.
Dr. Cheng obtained his BSc and PhD degrees in Biochemistry at the University of London and trained as a postdoctoral fellow in the field of tumor biology at the National Institute of Medical Research, U.K.
Paul Fonteyne, M.B.A.
Executive in Residence,
Canaan
Paul is the retired Chairman and CEO of Boehringer Ingelheim USA. He was with BI for 15 years in leadership roles both in the US and globally. From November 2011, he was President and CEO of Boehringer Ingelheim USA, and subsequently Chairman (retired 1/1/19). During this time, he led teams that grew sales and earnings several fold and participated in acquisitions and divestitures that led to a significantly greater focus on the US portfolio of companies in two main segments of Animal Health and Human Pharmaceuticals. During his 30+ years in the pharmaceutical industry, Paul also held commercial leadership roles at Merck and Abbott Laboratories.
Paul has served on the board of PhRMA, and chaired the National Pharmaceutical Council. Prior board experience includes ResTORbio Inc (reverse merger with Adicet Bio), AMAG (sale to Apollo backed Covis), and Covetrus (animal health company acquired by TPG and CD&R). Current public company board service includes Amylyx (AMLX) , and Apellis (APLS), and, Ypsomed AG (YPS), as well as several private companies.
Paul now serves as an Executive in Residence to Canaan, a Venture Capital Fund dedicated to Health Care and Technology early-stage investing. He advises several companies and is actively participating as a founder in biopharma university spinouts.
Paul holds dual citizenship in the USA and Belgium. He holds a MS in Chemical Engineering from the University of Brussels and an MBA for Carnegie Mellon University.
Josh Geballe, M.B.A.
Senior Associate Provost for Entrepreneurship and Innovation, Yale University;
Managing Director, Yale Ventures
Josh Geballe is Senior Associate Provost for Entrepreneurship and Innovation at Yale University and Managing Director of Yale Ventures. He is responsible for a wide range of services for students, faculty and the broader New Haven community to help launch new startups and provide training in entrepreneurship and innovation. Additional services include providing streamlined access to Yale intellectual property and sponsored research with Yale scholars, establishing partnerships to expand the impact of Yale discoveries, and growing the New Haven startup ecosystem.
Prior to joining Yale Ventures in 2022 Josh served as Chief Operating Officer for the State of Connecticut under Governor Ned Lamont. With responsibility for all executive branch agencies covering 30,000 employees he led successful initiatives to modernize state operations and expand the use of technology to improve services and reduce cost. In addition he led the state’s response to the COVID-19 pandemic, establishing nationally recognized programs for testing, contact tracing, nursing home protection, safe school operations and vaccination.
Prior to his three years in public service Josh spent his career in the technology industry, most recently as CEO of Core Informatics, a venture-backed scientific software company that was acquired by Thermo Fisher Scientific where he went on to serve as Vice President and General Manager of Digital Science. Previously he spent 11 years at IBM in a variety of international executive roles.
Josh holds an MBA from the Yale School of Management and a BA from Yale University.
John G. Houston, Ph.D.
President & CEO,
Arvinas
John G. Houston is currently the President & CEO of Arvinas and has over 28 years of experience in the pharmaceutical and biotech arena. Prior to this appointment, John was CSO and President of Research and Development at Arvinas. Before joining Arvinas, John was Senior Vice President of Specialty Discovery at Bristol-Myers Squibb where he worked for over 18 years in roles of increasing responsibility. He ran all of the disease science biology departments in research such as Oncology, Immuno-Oncology, Immuno-Sciences, Fibrotic Diseases, Genetically Defined Diseases, Neuroscience, Cardiovascular and Virology, as well as accountability for the various technology platform organizations such as Applied Biotechnology, Leads Discovery & Optimization, Genomics, Biologics Discovery California (formerly Medarex) and Zymogenetics in Seattle. For many years he was the global Disease Strategy Team co-chair for Neuroscience and the co-chair for the Neuroscience Early Assets development strategy. He was also the site head at the Wallingford, CT facility and a member of the BMS R&D Executive Committee reporting to the Head of Discovery. He also chaired the Target Portfolio Committee with governance accountability in the early research and development phase of the BMS portfolio.
With his teams and his BMS Research colleagues, he progressed over 180 compounds into early development, several of which have advanced into late stage clinical testing and beyond. He was a member of the BMS senior leadership team that achieved 14 NDA’s over a 10 year period.
John was also the principal architect and driver of the ‘Leveraging Technology’ initiative at BMS which oversaw the design and implementation of an industry leading integrated lead discovery and optimization process. This initiative created revolutionary changes in the discovery process at BMS with significant improvements in capacity, speed and cost control resulting in marked increases in research productivity and success rates.
Prior to joining Bristol-Myers Squibb, Dr. Houston worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit.
John completed post-doctoral studies with Professor Julia Douglas at Glasgow University, and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh.
Charles Lee, Ph.D., FACMG
Scientific Director and Professor,
The Jackson Laboratory for Genomic Medicine
Dr. Lee joined JAX Genomic Medicine from Harvard Medical School and Brigham and Women’s Hospital. He is best known for his discovery that copy–number variation—a state in which cells have an abnormal number of DNA sections, sometimes associated with susceptibility or resistance to disease—is widespread and significant in the human genome. This discovery, and his subsequent research, has provided tools that clinicians use to help them make accurate diagnoses for hundreds of thousands of genetic tests every year on conditions such as autism, birth defects and cancer.
Throughout his career, Dr. Lee has received numerous accolades and awards for his research into the human genome, including an Award from the American Association for Cancer Research and the 2008 Ho-Am Prize in Medicine. He is an elected fellow of the American Association for the Advancement of Science (AAAS) and a 2014 Thompson Reuters Citation Laureate.
Raja Mangipudy, Ph.D.
Senior Vice President, Global Head of Drug Safety Research and Development, Groton Site Director,
Pfizer
Raja Mangipudy is responsible for all aspects of non-clinical safety for small molecules, large molecules, vaccines and animal care and welfare across all therapeutic areas and sites.
Prior to joining Pfizer, Raja was Vice-President of Nonclinical Safety Evaluation and Global Veterinary Sciences at Bristol-Myers Squibb (BMS). He also served as Site Head of the company’s nonclinical safety facilities at its New Brunswick, New Jersey, location which is a major hub for BMS. Raja was responsible for global nonclinical safety evaluation across modalities and therapeutic areas including Cardiovascular, Metabolic, Oncology, Immunoscience, Neuroscience, Fibrosis and Virology.
He earned his Ph.D. at Northeast Louisiana University (now University of Louisiana Monroe) and is a Diplomate of the American Board of Toxicology. Prior to BMS, Raja held positions at Merck, Sanofi, Pharmacia, Upjohn and, for a brief time at the beginning of his career, served as part of the Pfizer sales force in India.
Jackie Schumacher
Head of Regulatory and Quality,
Rallybio
Jackie Schumacher is currently the Head of Regulatory and Quality at Rallybio where she is responsible for the regulatory strategy and operations across the portfolio along with Quality Assurance oversight. Prior to Rallybio, Jackie was the VP of Regulatory and Quality at Lyndra Therapeutics. Before Lyndra, Jackie spent most of her 35+ year career within Pfizer; starting as an analytical chemist followed by a long tenure within the CMC Regulatory organization in roles of increasing responsibility. She has led teams to develop successful global registration strategies for new small molecules, product enhancements, and complex/combination products and held regulatory leadership positions within the former Established Products Sterile Injectables organization. Within Pfizer she also expanded her experiences taking on business-facing/commercial roles for emerging markets and established products.
Jackie has served as a board member and chair for IPAC-RS, an industry consortium focused on strategic pharmaceutical and regulatory development objectives for orally inhaled and nasal drug products. She is currently on the board of directors for Women in the Enterprise of Science and Technology (WEST), a nonprofit dedicated to the advancement of women in science, technology, and engineering.
Jackie received a B.A. in chemistry and in classical studies from Hamilton College.
Erika Smith, M.B.A.
CEO,
ReNetX Bio, Inc.
Erika Smith is the CEO of ReNetX Bio, a clinical stage, venture funded company in New Haven, CT, committed to advancing first-in-class, disease modifying therapy in the central nervous system. Over the past 25 years Erika has held key executive roles at leading life-science including Respironics (Philips Healthcare), Hyperion and IVAX.
She also launched and led the advancement of three separate successful investment funds including the $25M Blavatnik Fund for Innovation at Yale, YEI Innovation Fund and the Bio-Life Fund at the Center for Innovative Technology in partnership with Johnson & Johnson.
Erika was awarded “Entrepreneur of the Year” in 2019 by BioCT and Women of Innovation in 2020 by the Connecticut Technology Council. She is on the board of Biotechnology Innovation Organization (BIO), Vice Chair of the Healthcare and Biotechnology Governor’s Workforce Council and an Entrepreneur in Residence at Technology Incubation Program (TIP) at UConn. She is an invited TedX presenter, taught life-science translational classes at the National Institutes of Health and Georgetown and co-authored a playbook for best practices of “Empowering Women Entrepreneurs” sponsored by JPMorgan Chase.
Erika holds a bachelor’s in Biomedical and Electrical Engineering and an MBA from Vanderbilt University.
J. Dormer Stephen, J.D.
Partner,
Shipman & Goodwin, LLP
Dormer Stephen is Co-Chair of Shipman & Goodwin’s Business and Finance Practice Group.
Dormer handles venture capital and private equity and debt transactions, mergers and acquisitions and general corporate matters. His practice involves the representation of Fortune 500 companies, private equity funds, emerging companies and investment banks in structuring, negotiating and documenting seed through later stage equity and debt investments, mezzanine financings, syndicated credit facilities, mergers, acquisitions and joint ventures, buyouts, rollup strategies, intellectual property transactions, work-outs and financial restructurings and general corporate matters. Constituent companies are in a broad range of industries including financial services, insurance, life sciences, media, software and telecommunications. He also represents public and private clients in an “outside general counsel” capacity. Roles include counseling on strategic initiatives (such as joint ventures, joint development projects and intellectual property licensing and collaboration), commercial contract matters (such as distribution and supply agreements, license agreements and employment agreements) and other general corporate matters (such as employment and severance matters, equity incentive plans, corporate governance, real estate matters and insurance matters). As a member of the firm’s Opportunity Zones team, Dormer advises clients on various aspects of the Qualified Opportunity Zones program.
Prior to joining Shipman & Goodwin, Dormer was a Partner in the Corporate Department of Dewey & LeBoeuf LLP.
Matt Storeygard, M.B.A.
Senior Managing Director, Venture Capital Investments
CT Innovations (CI)
Matt Storeygard is a Senior Managing Director on the Venture Team at Connecticut Innovations and leads the Bio/Healthcare team. At CI, he is responsible for sourcing and evaluating investment opportunities, structuring new investments and supporting the growth and success of portfolio companies post-investment. He leads much of CI’s digital health investing activities. He sits on the Board of Upswing Health, Inbox Health, Nest Collaborative, and Hubbub, and is a Board Observer on 5 additional Companies including Vita Health, Intellihealth, and ReferWell. Prior to CI, Matt’s experience includes five years at Cross Sector Consulting, where he provided strategic consulting services including planning, financial analyses, competitive analyses and implementation strategies for a variety of clients, including health care, education, community development finance and workforce organizations. Previously, he worked at the Urban Institute, where he developed predictive models to analyze the effects of health policy legislation.
Matt received his B.A. in Economics at Haverford College and an M.B.A.in Finance and Strategy at Yale School of Management.
Mike Stow, M.B.A.
Vice President of Global Marketing for Surgical Robotics
Medtronic
Mike Stow is an accomplished business leader with over 15 years of experience in medical technologies and leadership roles across marketing, strategy, and general management. He is passionate about solving clinical needs through innovation and has commercialized over 20 new technologies that positively impact millions of patients every year.
Mike’s current role is Vice President of Global Marketing at Medtronic. He is responsible for the launch of Medtronic’s new surgical robotics platform which he has taken from pre-market to over 20 countries. He is also an executive sponsor of Medtronic’s Young Professionals Connecticut chapter and actively involved in Medtronic’s Connecticut State Steering Committee.
Prior to his current role, Mike was with Hologic where he led their global Breast Health business and introduced the technology that now screens the majority of women in the US for breast cancer. He has experience across medical devices, surgical implants, surgical robotics, medical imaging, software and artificial intelligence.
Prior to Hologic, he held a variety of roles with Covidien/Medtronic in Norwalk and North Haven, Stanley Tools in New Britain, and as a design engineer for a small manufacturing company in Guilford, CT. Having lived and worked in Connecticut for over 20 years, Mike is passionate about improving the business environment for life sciences and related industries in the state.
Mike received an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Carnegie Mellon University. He has been a guest lecturer at Cornell and Quinnipiac and sponsored and judged the healthcare case competition at Yale.
Carter Winstanley
Principal,
Winstanley Enterprises
Carter Winstanley, a founder of Winstanley Enterprises, has 31 years of real estate development experience. He has developed a wide range of commercial real estate product types, with a particular expertise in the lab/biotech/technology space. Since the late 1990s, Mr. Winstanley has acquired and redeveloped over 4 million square feet of commercial real estate worth approximately $550 million. In New Haven, CT alone, Mr. Winstanley has acquired and redeveloped over 1.8 million square feet of commercial real estate.
Notable recent projects include the construction of a 14 story, 513,000 square foot Class A, LEED Platinum life sciences building in New Haven that is 100% leased to Yale University and Alexion Pharmaceuticals (the rare disease division of Astra Zeneca), the development of a neighboring 525,000 square foot Class A life sciences building that will be anchored by Arvinas and Yale University, and the multi-year redevelopment initiative of the former Winchester Arms Facility in the Science Park neighborhood in New Haven CT.
Mr. Winstanley has also worked with universities across the country, including Boston University, the University of Massachusetts, the University of Connecticut, and New York University on similar lab incubator programs. He has also developed telecom/data centers for FT Interactive Data Corp., Conversant Communications and AT&T Corp. Mr. Winstanley holds a B.A. from Colgate University.
Kaile Zagger
Healthcare Executive, Director & Co- Founder
Widely recognized as a Social Impact Leader and an expert in working to improve standards of care in healthcare, Kaile has spent her career elevating and progressing global healthcare through the introduction of groundbreaking products and disrupting conventional thinking in the global space.
Kaile began her career in the GE Global Leadership Development Program, and from there has enjoyed an illustrious 20+ years career in healthcare focusing on building, restructuring and transforming businesses that can create impact for patient care. She has expertise in launching global business divisions, converting standard of care across specialties, accelerating commercialization, restructuring organizations / turn-arounds and transforming cultures for high performance.
She is hailed by her peers as a “warrior for women and children,” has been recognized as a “Top Ten Chief Operating Officer Globally,” in 2021 and was awarded a coveted place as a “Top World Leader in Healthcare” in 2022.
Kaile has held a myriad of senior leadership positions in Fortune 50 companies such as Boston Scientific, Intuitive Surgical, GE Healthcare, Philips Healthtech and Change Healthcare. She has held various C Level positions in both private and publicly traded companies, as well as serving as a Director in both sectors. She has recently served in various C Level positions for venture capital / private equity backed companies in need of large-scale transformations. In addition to her many professional accomplishments, Kaile is also Co-Founder of the MAT Foundation which serves to eradicate late-stage diagnosis of female cancers.
Kaile is highly also active in our community and serves as a speaker for universities, an author for Worth Media and has been adorned with two State of Connecticut Proclamations that were awarded to her for her philanthropic work in advocation for women and work contributing to preventative disease. She has a deep network within the healthcare industry and is widely respected as a visionary that repeatedly leads the industry towards progression and advancement.